Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer.
about
Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients.The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors.Maternal and female fetal testosterone levels are associated with maternal age and gestational weight gain.The effect of exercise on body composition and bone mineral density in breast cancer survivors taking aromatase inhibitors.
P2860
Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Genetic polymorphism at Val80 ...... tors for ER (+) breast cancer.
@ast
Genetic polymorphism at Val80 ...... tors for ER (+) breast cancer.
@en
type
label
Genetic polymorphism at Val80 ...... tors for ER (+) breast cancer.
@ast
Genetic polymorphism at Val80 ...... tors for ER (+) breast cancer.
@en
prefLabel
Genetic polymorphism at Val80 ...... tors for ER (+) breast cancer.
@ast
Genetic polymorphism at Val80 ...... tors for ER (+) breast cancer.
@en
P2093
P2860
P1476
Genetic polymorphism at Val80 ...... itors for ER (+) breast cancer
@en
P2093
Antonella Rastelli
Cynthia Ma
Reina Armamento-Villareal
Swapna Vattikuti
P2860
P304
P356
10.1097/FPC.0000000000000146
P577
2015-08-01T00:00:00Z